年龄和性别对血小板数量的影响:对优化增长因子丰富的血制剂的影响
Arturo Sánchez-Pérez1, Ana Palma-Sánchez2, Alfonso Jornet-García1
1Department of Periodontology. Faculty of Medicine and Dentistry. University of Murcia. Spain.
Journal of clinical and experimental dentistry
|December 29, 2025
概括
血小板数量因年龄和性别而异. 这项研究发现,血小板数量随着年龄的增长而下降,这表明根据患者的人口统计数据,对血小板丰富血 (PRP) 疗法的血液提取进行调整.
科学领域:
- 生物医学科学 生物医学科学
- 再生医学是一种再生医学.
- 血液学 血液学 血液学
背景情况:
- 富含生长因子的血 (GFRP) 促进组织再生,在牙科中用于愈合和骨质整合.
- 富血小板血 (PRP) 是GFRP的关键成分,是一种富含生长因子的自身血源.
- 优化GFRP疗法需要了解影响血小板度的因素.
研究的目的:
- 为了研究年龄和性别对血小板数量的影响.
- 为促进富血小板血 (PRP) 疗法的标准化提供信息.
主要方法:
- 这是一项对384名患者的横截面研究.
- 患者被分为六个年龄段.
- 根据年龄和性别分析了血小板计数,并进行了相关性分析.
主要成果:
- 平均血小板数量在女性中略高于男性,但不具有统计学意义 (p=0.113).
- 在年龄和血小板计数之间观察到统计学上显著的负相关性 (r=-0.175,p<0.01).
- 血小板数往往会随着年龄的增长而减少.
结论:
- 人口血小板计数表现出变化.
- 用于PRP制剂的血液提取协议应考虑患者的年龄和性别.
- 根据人口统计数据调整PRP制剂可能会优化治疗结果.
相关概念视频
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
209
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
209
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
216
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
216
Pharmacodynamics in Geriatric Patients: Effects of Age
174
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
174
Structure and Function of Platelets
2.8K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.8K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
178
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
178
Factors Affecting Protein-Drug Binding: Patient-Related Factors
277
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
277


